[Effects in tetramethylpyrazine on TXA2 and PGI2 by cardio-pulmonary bypass in congenital heart diseases with pulmonary hypertension patients].
OBJECTIVE
To study protective effects of tetramethylpyrazine (TMP) on the imbalance of TXA2/PGI2 during cardiopulmomary bypass (CPB) in congenital heart disease (CHD) with pulmonary hypertension (PH) patients.


METHODS
Thirty patients suffered from non-cyanotic CHD-PH were randomly divided into control group (n = 15) and treatment group (n = 15). 3 mg/kg of TMP was dripped intravenously after anesthesia and 1 mg/kg of TMP was infused into oxygenator after CPB individually. Blood samples were collected and TXA2 as well as PGI2 were measured after anesthesia induction, 15 min during CPB, 5 min after release of the aortic cross-clamp, and 20 min, 6 hrs and 24 hrs after CPB.


RESULTS
There was significant difference between treatment group and control group except before operation and 24 hrs after CPB.


CONCLUSIONS
The imbalance of TXA2 and PGI2 in patients with CHD-PH during CPB could correct by TMP.
Huang
R
R
Department of Thoracic and Cardiovascular Surgery, First Affiliated Hospital, Fujian Medical University, Fuzhou 350005.
Liao
C
C
Chen
D
D
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000293:Adolescent; D000328:Adult; D002315:Cardiopulmonary Bypass; D002648:Child; D002675:Child, Preschool; D005260:Female; D006344:Heart Septal Defects, Atrial / Q000097:blood / Q000150:complications / Q000601:surgery*; D006345:Heart Septal Defects, Ventricular / Q000097:blood / Q000150:complications / Q000601:surgery*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood* / Q000209:etiology; D008297:Male; D011719:Pyrazines / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D011719:Pyrazines; D014665:Vasodilator Agents; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C017953:tetramethylpyrazine